Compare MGM Resorts International (MGM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Merck & Co., Inc. — how do they compare? MGM Resorts International trades at $46.77 (market cap $11.80B), while Merck & Co., Inc. trades at $126.75 (market cap $314.90B). The key difference: Merck & Co., Inc. is far larger — about 26.7× MGM Resorts International's market cap, and Merck & Co., Inc. pays the higher dividend (2.67%). Which is the better fit depends on your goals.
| MGM | MRK | |
|---|---|---|
Market Cap | $11.80B | $314.90B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $129.52 |
52-Week Low | $30.72 | $77.60 |
Enterprise Value | $40.85B | $358.32B |
Dividend Yield | 0.03% | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $46.13, down 1.64% on the day, amid ongoing acquisition discussions with Barry Diller's People Inc. at a proposed $48.30 per share. The stock shows a bullish technical trend with moving averages supporting upside, while fundamentals reveal modest revenue growth to $17.54B in 2025 but declining net income margins to 1.03%. Analyst sentiment is mixed with a consensus price target of $48.93, reflecting a near-term catalyst from potential M&A activity.
The outlook hinges on the acquisition outcome, offering upside to the bid price, but execution risks and margin pressures pose challenges. Investors face event-driven volatility, with the stock's trajectory dependent on deal finalization and operational improvements in a competitive gaming sector.
Merck (MRK) trades at $127.50, down slightly by 0.14% today. The stock exhibits a bullish technical trend with strong moving average signals and is trading near its pivot point of $128. Fundamentally, the company reported solid 2025 results with revenue of $65.01 billion and net income of $18.25 billion, though 2026 net income is projected to decline. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for Merck is supported by analyst optimism, with a consensus price target of $137.30 and 68% buy ratings. Key opportunities include pipeline expansion through acquisitions and strong profitability metrics. Risks involve projected earnings volatility in 2026, competitive pressures in oncology, and macroeconomic factors affecting pharmaceutical valuations. The stock presents a growth-oriented case with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
